Skip to main content
Clinical Trials/NL-OMON50131
NL-OMON50131
Completed
Not Applicable

In vitro characterization of the immune response of recovered COVID-19 patients and healthy controls to SARS-CoV-2. - Recovered Covid-19 patients blood sampling

ISA Pharmaceuticals B.V.0 sites14 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Corona
Sponsor
ISA Pharmaceuticals B.V.
Enrollment
14
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
ISA Pharmaceuticals B.V.

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria for both recovered COVID\-19 patients and healthy participants
  • 1\. Participant must sign the study informed consent form prior to any
  • study\-mandated procedure indicating that he or she understands the purpose,
  • procedures and potential risks, and is willing to participate in the study;
  • 2\. Participant is male or female and between 18 and 65 years of age, inclusive,
  • at the time of enrollment;
  • 3\. Participant is willing and able to complete the study procedures;
  • 4\. Participant has a primary care physician at the time of enrollment;
  • 5\. Participant is not taking any immunosuppressive medication or other
  • immunomodulating agents (including investigational drugs) for at least 3 weeks

Exclusion Criteria

  • Exclusion criteria for both recovered COVID\-19 patients and healthy participants
  • 1\. Participant with a whole blood donation or loss of \>500 ml within 21 days
  • before study blood sampling;
  • 2\. Any known factor, condition, or disease that might interfere with
  • compliance, study conduct or interpretation of the results, as deemed by the
  • investigator.
  • Exclusion criteria for healthy participants only
  • 1\. Participant reports a previous positive diagnostic test result for
  • SARS\-CoV\-2 infection (serological testing or viral RNA detection by PCR
  • 2\. Participant developed clinically overt symptoms of COVID\-19 following close

Outcomes

Primary Outcomes

Not specified

Similar Trials